Background: Mast cells (MCs) are multifunctional effector cells of the immune system. These cells originate from pluripotent hemopoietic progenitors. In contrast to basophils and other leukocytes, MCs exhibit a remarkably long life span (years) in vivo. Although a role for stem cell factor (SCF) and SCF receptor (KIT) in long-term survival of MCs has been proposed, the underlying biochemical mechanisms remain unknown. Materials and Methods: We have examined expression of ‘survival-related’ molecules of the bcl-2 family including bcl-2 and bcl-xL, in primary human MCs and the human MC line HMC-1. Primary MCs were isolated from dispersed lung tissue by cell sorting using an antibody against KIT. mRNA expression was analyzed by RT-PCR and Northern blotting. Results: As assessed by RT-PCR, purified unstimulated lung MCs (>98% pure) exhibited KIT- and bcl-xL mRNA, but did not express bcl-2 mRNA. However, exposure of lung MCS to SCF (100 ng/ml) for 8 h resulted in expression of bcl-2 mRNA. Corresponding results were obtained by immunocytochemistry. In fact, exposure of MC to SCF resulted in expression of the bcl-2 protein whereas unstimulated MCs displayed only the bcl-xL protein without expressing the bcl-2 protein. The human MC leukemia cell line HMC-1, which contains a mutated and intrinsically activated SCF receptor, showed constitutive expression of both bcl-2 and bcl-xL at the mRNA and protein level. Conclusion: Our data show that human MCs can express members of the bcl-2 family. It is hypothesized that bcl-xL plays a role in KIT-independent growth of MCs, whereas bcl-2 may be involved in KIT-dependent functions of MCs.

Keywords:
Apoptosis, bcl-2,bcl-xL, c-KIT, Mastocytosis
1.
Metcalf D: The molecular control of cell division, differentiation commitment and maturation in hemopoietic cells. Nature 1989;339:27–30.
2.
Wickremasinghe RG, Hoffbrand AV: Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies. Blood 1999;93:3587–3600.
3.
Peters R, Leyvraz S, Lucien P: Apoptotic regulation in primitive hematopoietic precursors. Blood 1998;92:2041–2052.
4.
Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717–1725.
5.
Yang E, Korsmeyer SJ: Molecular thanatoposis: A discourse on the bcl-2 family and cell death. Blood 1996;88:386–405.
6.
Reed JC: Double identity for proteins of the bcl-2 family. Nature 1997;387:773–776.
7.
Amati B, Land H: Myc-Max-Mad: A transcription factor network controlling cell cycle progression, differentiation, and death. Current Opin Gen Develop 1994;4:102–108.
8.
Miyashita T, Krajewsky S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799–1805.
9.
Reed JC: Cytochrome c: Can’t live with it – can’t live without it. Cell 1997;91:559–560.
10.
Salvesen GS, Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell 1997;91:443–446.
11.
White E: Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:1–15.
12.
Serafin WE, Austen KF: Mediators of immediate hypersensitivity reactions. N Engl J Med 1987;317:30–34.
13.
Galli SJ: Biology of disease: New insights into ‘the riddle of the mast cells’: Microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990;62:5–33.
14.
Födinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, Valent P, Mannhalter C: Origin of human mast cells: Development from transplanted hemopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994;84:2954–2959.
15.
Mekori YA, Oh CK, Metcalfe DD: The role of c-kit and its ligand, stem cell factor, in mast cell apoptosis. Int Arch Allergy Immunol 1995;107:136–138.
16.
Valent P, Spanblöchl E, Sperr WR, Sillaber Ch, Agis H, Zsebo K, Geissler K, Bettelheim P, Lechner K: Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture. Blood 1992;80:2237–2245.
17.
Valent P: The riddle of the mast cell: c-kit ligand as missing link ? Immunol Today 1994;15:111–114.
18.
Kitamura Y, Go S, Hatanaka K: Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978;52:447–452.
19.
Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ: The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 1994;144:321–328.
20.
Yee NS, Paek I, Besmer P: Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. J Exp Med 1994;179:1777–1787.
21.
Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, Maurer D, Bettelheim P: Mast cell typing: Demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989;73:1778–1785.
22.
Willheim M, Agis H, Sperr WR, Köller M, Bankl HC, Kiener H, Fritsch G, Füreder W, Spittler A, Graninger W, Scheiner O, Gadner H, Lechner K, Boltz-Nitulescu G, Valent P: Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and CD117/c-kit. J Immunol Methods 1992;182:115–129.
23.
Butterfield JH, Weiler D, Dewald G, Gleich GJ: Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345–355.
24.
Baghestanian M, Hofbauer R, Kiener H, Bankl HC, Wimazal F, Willheim M, Scheiner O, Füreder W, Müller MR, Bevec D, Lechner K, Valent P: The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein 1 (MCP-1) in human lung mast cells. Blood 1997;90:4438–4449.
25.
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindstein T, Turka LA, Mao X, Nunez G, Thompson CB: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597–608.
26.
Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986;47:19–28.
27.
Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609–619.
28.
Jordan H, Walchshofer S, Jurecka W, Mosberger I, Sperr WR, Wolff K, Chott A, Bühring HJ, Lechner K, Horny H-P, Valent P: Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/kit, and bcl-xL. Hum Pathol 2001;32:545–552.
29.
Baghestanian M, Bankl HC, Sillaber C, Beil WJ, Radaszkiewicz T, Füreder W, Preiser J, Vesely M, Schernthaner G, Lechner K, Valent P: A case of malignant mastocytosis with circulating mast cell precursors: Biologic and phenotypic characterization of the malignant clone. Leukemia 1996;10:159–166.
30.
Moulding DA, Akgul C, Derouet M, White MR, Edwards SW: BCL-2 family expression in human neutrophils during delayed and accelerated apoptosis. J Leukoc Biol 2001;70:783–792.
31.
Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I, Senju S, et al: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995;267:1506–1510.
32.
Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75:229–240.
33.
Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K, Zangemeister-Wittke U, Akbar AN, Simon HU: Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 1998;92:778–783.
34.
Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA: The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci USA 1994;91:7553–7557.
35.
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y: Identification of mutation in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736–1744.
36.
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312–314.
37.
Cervero C, Escribano L, San Miguel JF, Diaz-Augustin B, Bravo P, Villarrubia J, Garcia-Sanz R, Velasco JL, Herrera P, Vargas M, Gonzalez M, Navarro JL, Orfao A: Expression of Bcl-2 by human bone marrow mast cells and its over-expression in mast cell leukemia. Am J Hematol 1999;60;191–195.
38.
Schandl CA, Li S, Re GG, Fan W, Willingham MC: Mitotic chromosomal bcl-2. I. Stable expression throughout the cell cycle and association with isolated chromosomes. J Histochem Cytochem 1999;47:139–149.
39.
Schandl CA, Li S, Re GG, Fan W, Willingham MC: Mitotic chromosomal bcl-2. II. Localization to interphase nuclei. J Histochem Cytochem 1999;47:151–158.
40.
Gurish MF, Friend DS, Webster M, Ghildyal N, Nicodemus CF, Stevens RL: Mouse mast cells that possess segmented/multi-lobular nuclei. Blood 1997;90:382–390.
41.
Agis H, Beil WJ, Bankl HC, Füreder W, Sperr WR, Ghannadan M, Baghestanian M, Sillaber C, Bettelheim P, Lechner K, Valent P: Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes, diagnostic role of cell-immunophenotyping. Leuk Lymphoma 1998;2:187–204.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.